
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

**CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934**

April 9, 2003

(Date of earliest event reported)

MEDICAL DISCOVERIES, INC.

(Exact name of registrant as specified in its charter)

Utah

0-12627

87-0407858

(State or other jurisdiction of incorporation or
organization)

(Commission File No.)

(I.R.S. Employer Identification No.)

738 Aspenwood Lane
Twin Falls, Idaho 83301
(208) 736-1799

(Address of principal executive offices and telephone number, including area code)

TABLE OF CONTENTS

[Item 9. Regulation FD Disclosure](#)

[SIGNATURES](#)

[INDEX OF EXHIBITS](#)

[EXHIBIT 99](#)

Item 9. Regulation FD Disclosure

This Current Report on Form 8-K is filed for the purpose of disclosing the press release that was released on April 9, 2003 and is attached hereto as Exhibit 99.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

MEDICAL DISCOVERIES, INC.

/s/ Judy M. Robinett

Judy M. Robinett
President and Chief Executive Officer

Date: April 9, 2003

INDEX OF EXHIBITS

Number	Description
99	Press Release issued April 9, 2003

CONTACT:
MDI (208) 736-1799

FOR IMMEDIATE RELEASE

MEDICAL DISCOVERIES, INC. REVIEWS IP AND RECEIVES NEW PATENT

Mayer, Brown, Rowe & Maw To Focus on Patent Strategy

TWIN FALLS, Idaho, April 9, 2003 — Medical Discoveries, Inc. (OTC Bulletin Board: MLSC) has retained global legal giant Mayer, Brown, Rowe & Maw to strengthen and expand MDI's intellectual property and assets and provide worldwide strategic partnering and regulatory compliance advice. MDI has also received the company's eleventh patent relating to the company's proprietary drug MDI-P.

Among the 10 largest law firms in the world, Mayer, Brown, Rowe & Maw provides comprehensive legal services to biotech, pharma, life science, bioinformatics, medical device and agribusiness companies, as well as to their investors and financiers, throughout the United States, Canada, Europe, Asia and Latin America. The firm also has consulting offices in Beijing and Shanghai, as well as an independent correspondent relationship with Jáuregui, Navarrete, Nader y Rojas, S.C., one of Mexico City's most respected law firms. "MDI's technology and corporate vision provides an excellent opportunity to be the legal partner in taking a company from its pre-market stage to a successful market launch. Our commitment to MDI and MDI's vision will make them a market leader going forward," according to Diane Romza-Kutz, partner in the Biotech Pharma Life Sciences Practice at Mayer Brown Rowe & Maw.

Medical Discoveries, Inc. has received, from Mexico's Patent And Trademark Office, notice of entry into National Phase of the company's International PCT Application No. PCT/US95/10777, Patent Application No. 971408, entitled "System For Electrolyzing Fluids For In Vivo Administration For Humans And Other Warm Blooded Mammals."

Medical Discoveries, Inc. now has a total of eleven granted patents relating to the company's proprietary electrolysis devices, methods, and the patented products and applications derived therein. MDI's patents and resulting intellectual properties now span more than a decade of research and development. Medical Discoveries, Inc. was formed in 1991 to investigate and develop effective, rapid acting and safe pharmaceuticals capable of destroying viruses, bacteria and fungi.

Formed in 1991, Medical Discoveries, Inc. is a publicly traded (OTC Bulletin Board: MLSC) development-stage biopharmaceutical research company (as defined in SFAS No.7) engaged in the research, development and validation of a novel class of drugs, based upon the company's patented and proprietary electrolysis technologies. MDI is developing active anti-viral, anti-bacterial and anti-fungal agents for a variety of applications including the treatment of HIV/AIDS.

Information in this press release relating to the potential of MDI constitutes forward-looking statements. Actual results in future periods may differ materially from the forward-looking statements because of a number of risks and uncertainties, including but not limited to: MDI's lack of significant operating revenue to date; MDI's need for substantial and immediate additional capital; the fact that MDI may dilute existing shareholders through additional stock issuances; the extensive governmental regulation to which MDI is subject; the fact that MDI's technologies remain unproven; the intense competition MDI faces from other companies and other products; and MDI's reliance upon patents and other intellectual property that may not provide meaningful protection against competitors. Additional information about these and other factors that could affect MDI's business is set forth in MDI's 2002 Annual Report on Form 10-KSB and other filings with the Securities and Exchange Commission.

###